Quality of life and voice outcome of patients treated with transoral CO2 laser microsurgery for early glottic carcinoma (T1–T2): a 2-year follow-up study

Martine Hendriksma1 · Yda van Loon1 · W. Martin C. Klop2 · Marieke M. Hakkesteegt3 · Bas J. Heijnen1 · Ib tessam el Hasnaoui1 · Martin de Jong4 · Ton P. M. Langeveld1 · Peter Paul G. van Benthen1 · Robert J. Baatenburg de Jong3 · Elisabeth V. Sjögren1

Received: 22 October 2018 / Accepted: 13 February 2019 / Published online: 27 February 2019
© The Author(s) 2019

Abstract
Purpose Longitudinal studies in laryngeal cancer can provide clinicians information about short-term and long-term functional outcomes, like quality of life (QoL) and voice outcome. This information is important when counseling patients or choosing a primary treatment modality. The present study assessed long-term (2 years) QoL and voice outcome in patients with extended T1 and limited T2 glottic carcinoma treated with transoral CO2 laser microsurgery (TLM) (unilateral type III or bilateral type II resections).

Methods Three questionnaires were administered: the Voice Handicap Index (VHI), the European Organization for Research and Treatment of Cancer (EORTC) QoL questionnaire (QLQ)-C30, the EORTC QLQ-HN35. A perceptual voice evaluation at six different time points was conducted: preoperatively, and postoperatively at 6 weeks, 3 months, 6 months, 1 year, and 2 years. Fluctuations over time were investigated.

Results Sixty-one patients were included in the analysis. Patients reported high-level functioning and low symptom scores 2 years postoperatively. Gender significantly affected the VHI scores at 2 years (mean VHI scores: female 8.7 vs. male, 23.9; p = 0.023). The major improvement in VHI scores was observed within the first 6 months. The tumor stage (T1a, T1b, and T2) significantly impacted the grade (mean scores at 2 years: 1.0, 1.9, and 1.7; p = 0.001). These scores stabilized at 6 months.

Conclusions Patients show good long-term QoL with low symptom scores, a low voice handicap, and mild to moderate dysphonia, 2 years postoperatively. Scores stabilize at 6 months and provide a clear indication of status at 1 and 2 years.

Keywords Early glottic carcinoma · TLM · Laser surgery · Quality of life · Voice outcome · Questionnaire

Introduction

Early glottic carcinoma (Tis-T2) can be treated effectively with radiotherapy or transoral CO2 laser microsurgery (TLM). According to the Dutch Guidelines for laryngeal carcinoma, TLM is the advocated treatment for superficial midcord T1a glottic carcinoma, and radiotherapy is indicated for more extended T1 and T2 glottic carcinomas [1]. Studies have shown that both therapies provided good, comparable oncological results [2–4], but some studies show superior laryngeal preservation after TLM [5–8]. There is less data on the functional outcomes of these treatment modalities, such as quality of life (QoL) and voice outcome, particularly in patients with T2 glottic carcinoma [7]. The lack of these data often prohibits adequate comparisons of modalities in patient counseling.
Although oncological results play a highly significant role in selecting the treatment modality, functional outcomes are also important when determining the patient’s treatment preferences. Each treatment modality has different side effects, and patients may have different preferences regarding the trade-offs. Therefore, treatment decisions for early glottic carcinoma should be based on both oncological and functional outcomes including patients’ preferences.

Several studies have investigated QoL in patients with early glottic carcinoma after treatment with radiotherapy or TLM [9–13]. Most have reported good postoperative QoL scores that were either the same or better than preoperative scores. A questionnaire that is often used and has a well-proven method to measure QoL in cancer patients is the European Organization for Research and Treatment of Cancer (EORTC) QoL questionnaire (QLQ) C30, which is a general questionnaire. This can be complemented with the specific head and neck cancer module, the EORTC QLQ-HN35. Both questionnaires ask the patient to rate their problems associated with their tumor and subsequent treatment and to reflect on their QoL. Voice outcome has also been studied in early glottic carcinoma after treatment with either radiotherapy or TLM. These studies showed that voice outcome improved significantly postoperatively after the treatment of Tis-T1a tumors (radiotherapy and TLM) or after limited resections (types I–II) (TLM) [12, 14, 15].

When the voice changes, it often affects patient’s self-perception, as well as how others perceive their voice. Although many acoustic and aerodynamic parameters can be determined, these perceptive changes, such as dysphonia in the form of hoarseness or breathiness and an increase in vocal effort, are often the most fundamental to the patients and their surroundings. Therefore, measures of voice outcome that are often used in the clinical setting are self-assessment tools such as the Voice Handicap Index (VHI) and perceptual evaluation tools, such as the GRBAS rating scale.

Both QoL and voice outcomes may vary, mainly depending on the timing of the evaluation [16]. Most prospective studies have reported preoperative and 3- to 12-month postoperative functional outcomes; in contrast, cross-sectional studies have only reported postoperative results, with large variations in time frames. The advantage of longitudinal studies is that they can assess changes over time and determine when a stable condition is achieved. This information can support clinicians in counseling patients about their long-term expectations, an essential component of a well-informed treatment decision. In light of these findings, and due to the lack of long-term functional outcome data, the present study aimed to (1) assess long-term (2-year) results of QoL and voice outcome in patients treated with TLM for extended T1 and limited T2 glottic tumors and (2) investigate fluctuations over time, based on prospectively collected data.

**Methods and materials**

**Patients**

From December 2009 to March 2015, this non-randomized, prospective, longitudinal outcome study was conducted at the University Cancer Center, Leiden, The Hague, the Erasmus Medical Center, and The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital in The Netherlands. Included patients were those with extended T1N0 and limited T2N0 glottic carcinomas, which would require a unilateral transmucosal resection [European Laryngological Society (ELS) classification [17] type III] or a bilateral subligamental resection (type II), if treated surgically. All patients with lesions that met these criteria were offered a treatment choice between TLM and radiotherapy. Patients made their choice after comprehensive counseling (described elsewhere in detail by van Loon et al. [18]). After stroboscopy, the definite tumor stage was determined endoscopically under general anesthesia.

Patients that met the inclusion criteria after endoscopy were enrolled in the study at that time. In case of T1b tumors, some procedures were staged to prevent web formation. The QoL and voice outcome were assessed with patient self-report questionnaires and perceptual voice analyses conducted at various time points during follow-up. The study was approved by the local Medical Ethics Committees at all three hospitals. Informed consent was obtained from all patients before inclusion into the study.

**Questionnaires**

We implemented three self-administered, validated questionnaires: the VHI-30 [19], the EORTC QLQ-C30 version 3 [20], and the EORTC QLQ-HN35 [21]. Each was assessed at six different time points: preoperatively, and postoperatively, at 6 weeks, 3 months, 6 months, 1 year, and 2 years. Patients were asked to complete the questionnaires unaided during their visit to the outpatient clinic.

**Voice Handicap Index**

The Dutch version of the VHI is a validated 30-item questionnaire. It measures the psychosocial effects of voice impairments in daily life. Patients score each item by selecting a response from a five-point Likert scale, which ranges from 0 to 4 (0 = never, 4 = always). The sum of scores results in a total VHI score, which ranges from 0 to 120. A higher score indicates a worse voice-related
outcome [19, 22]. A difference of ten points or more has been shown to be clinically relevant [23].

**EORTC QLQ-C30**

The EORTC-QLQ-C30 evaluates health-related QoL for the general population of patients with cancer. This questionnaire comprises 30 questions that address patient function and symptomatology over the preceding week. The questionnaire includes a global health status scale, five functional scales (physical, role, emotional, cognitive, and social), three multi-item symptom scales (fatigue, pain, and nausea and vomiting), and six single items that assess additional symptoms in patients with cancer (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Patients score each item by selecting a response from a four-point Likert scale from 1 (not at all) to 4 (very much), except for the global health status, which is scored from 1 (very poor) to 7 (excellent). These scores are transformed to a scale of 0–100. A higher score represents a higher (better) level of functioning or a higher (worse) level of symptoms [20]. A difference of ten points has been shown to be clinically relevant [24, 25].

**EORTC QLQ-HN35**

The EORTC QLQ-HN35 evaluates health-related QoL for patients with head and neck cancer. It is often used to complement the EORTC QLQ-C30. This questionnaire contains 35 questions that address symptoms and side effects of treatment, social function, and body image/sexuality. The questionnaire incorporates 7 multi-item scales: pain, swallowing, senses (taste and smell), speech, social eating, social contact, and sexuality; and 11 single items: teeth, opening mouth, dry mouth, sticky saliva, coughing, feeling ill, use of analgesics, nutritional supplements, feeding tube, weight loss, and weight gain. Each item is evaluated by selecting a response from a four-point Likert scale, the same as the scales used for the EORTC QLQ-C30. The final scores are transformed to a scale of 0–100. A higher score represents more severe problems or symptoms [21, 26]. A change of ten points has been shown to be clinically relevant [26].

**Perceptual evaluation and voice recording**

Perceptual evaluation was performed with the GRBAS rating scale on a 30-s running speech sample. Recordings were acquired at a sampling frequency of 44.1 kHz with a dual microphone headset recorder (Alphatron Medical Systems) and a Beyer dynamic microphone, in a noise-free environment. The speech sample consisted of a standard, phonetically balanced Dutch text, “80 dappere fietsers” [80 brave cyclists]. The GRBAS rating scale consisted of five scales (grade, roughness, breathiness, asthenia, and strain), of which only the grade of dysphonia was rated because it reflects the overall degree of hoarseness or the severity of the voice abnormality [27]. Each sample was scored on a scale of 0 (normal voice) to 3 (severe dysphonic voice), and a higher score represented a more dysphonic voice [28]. A panel of four experienced listeners consisting of three speech–language pathologist and one ENT surgeon/laryngologist, all specialized in both oncological and benign voice pathology and treatment (B.J.H., M.M.H., V.A.H. vdK., E.V.S.), and blinded to all data scored the grade of dysphonia. In those cases where the experts rated the voice differently, consensus was reached through re-evaluation of the speech sample and discussion. The intrarater reliability of our experts was of 0.91 (95% CI 0.89–0.93).

**Statistical methods**

Statistical analyses were performed with SPSS version 23.0 (IBM Corp. Armonk, NY, USA). Assumptions of normality were assessed. The effect of time on the different questionnaires was assessed with the linear mixed model analysis; the model was adjusted for four possible confounders: gender, tumor stage, type of resection (unilateral type III vs. bilateral type II), and involvement of the anterior commissure (AC; no involvement vs. unilateral or bilateral involvement). Additionally, the least significant difference (LSD) post hoc test was used to adjust for multiple comparisons. The linear mixed model method was chosen, since it applies a correction for missing data. This correction is based on the observed data, and it uses all available information, without the need to censure an entire set of patient data, when one or more data points are missing or the need for imputation of measurements [29]. A p value of 0.05 was considered statistically significant.

**Results**

**Patients**

One hundred and seventy-five patients with suspected or proven extended T1 and limited T2 glottic tumors were identified as candidates for the study. Of these, 89 were suitable for inclusion, based on endoscopy. Of these, 13 patients were lost to follow-up or discontinued participation in the first 3 months of the study. During the 2 years of follow-up, five patients died, due to unrelated causes, and ten patients developed recurrent disease. Thus, the final cohort comprised 61 patients for analysis (Fig. 1). The baseline characteristics of these patients are presented in Table 1.
Voice Handicap Index

The mean VHI score improved significantly over time, ranging from 30.5 preoperatively to 21.8 at 2 years (Δ8.7, \( p = 0.003 \)). However, according to our definition, this improvement did not qualify as clinically relevant. The major improvement in the VHI score occurred within the first 6 months (Δ7.2). Thereafter, only small additional improvements were noted between 6 months and the 2-year follow-up. Gender was the only variable that significantly affected the VHI score; the difference in mean VHI scores was 11.6 points (\( p = 0.023 \)) between male and female patients. The difference in mean VHI score per time point between male and female patients was 7.8 points (\( p = 0.204 \)) preoperatively, 14.6 points (\( p = 0.025 \)) at 6 weeks, 11.0 points (\( p = 0.090 \)) at 3 months, 15.4 points at 6 months (\( p = 0.018 \)), 5.9 points (\( p = 0.346 \)) at 1 year, and 15.1 (\( p = 0.039 \)) points at 2 years. At 2 years, females showed a lower (normalized) VHI score and a larger improvement (Δ15.3) than males. Additionally, unlike the improvement observed in male patients, the improvement in the mean VHI score in female patients was clinically relevant (Table 2).

Table 1 Baseline characteristics

| Characteristics                        | Number of patients (%) |
|----------------------------------------|------------------------|
| Total = 61 (100%)                      |                        |
| Mean age at surgery, years (SD)        | 67.6 (8.90)            |
| Gender                                 |                        |
| Male                                   | 51 (83.6)              |
| Female                                 | 10 (16.4)              |
| Tumor stage                            |                        |
| T1a                                    | 29 (47.5)              |
| T1b                                    | 19 (31.1)              |
| T2                                     | 13 (21.3)              |
| Resection (ELS classification)         |                        |
| Type III                               | 38 (62.3)              |
| Type II bilateral                      | 23 (37.7)              |
| AC involvement                         |                        |
| No                                     | 12 (19.7)              |
| Unilateral                             | 26 (42.6)              |
| Bilateral                              | 23 (37.7)              |

AC anterior commissure, ELS European Laryngological Society, SD standard deviation
Patients showed good global health status preoperatively and the improvement in global health status over time was only borderline significant. It increased from 77 preoperatively to 81 at 2 years postoperatively ($\Delta4$, $p=0.047$). However, this improvement did not qualify as clinically relevant. The results of the different functional scales showed that patients reported high levels of functioning. In all five scales, scores ranged from 88 to 97 points after 2 years. One of these scales—the emotional functioning scale—showed a significant and clinically relevant improvement ($\Delta18; p<0.001$), compared to preoperative values. The results of the symptom scales showed that patients also reported high levels of functioning on all items during the 2-year follow-up. The most common complaints were fatigue, dyspnea, and insomnia; scores ranged between 9 and 15 points. Only the change in insomnia showed a significant and clinically relevant improvement compared to preoperative values ($\Delta11; p<0.025$) (Table 3).

### Table 2 Voice Handicap Index and perceptual evaluation results

| Groups            | Preoperative Mean | 6 weeks Mean ($\Delta$) | 3 months Mean ($\Delta$) | 6 months Mean ($\Delta$) | 1 year Mean ($\Delta$) | 2 years Mean ($\Delta$) | $p$ value |
|-------------------|-------------------|-------------------------|--------------------------|--------------------------|------------------------|-------------------------|-----------|
| Voice Handicap Index          | Overall ($n=61$)  | 30.5                    | 30.7 (0.23)              | 27.0 (−3.5)              | 23.3 (−7.2)            | 23.8 (−6.7)             | 21.8 (−8.7) | 0.003     |
|                               | Male ($n=51$)     | 31.8                    | 33.1 (1.3)               | 28.8 (−3.0)              | 25.7 (−6.0)            | 24.8 (−6.9)             | 23.9 (−7.9) | <0.001    |
|                               | Female ($n=10$)   | 24.0                    | 18.5 (5.5)               | 17.8 (−6.2)              | 10.4 (13.6)            | 18.9 (−5.1)             | 8.7 (−15.3) | 0.111     |
| Perceptual evaluation—grade   | Overall ($n=61$)  | 1.5                     | 1.9 (0.41)               | 1.6 (0.11)               | 1.4 (−0.11)            | 1.3 (−0.20)             | 1.4 (−0.05) | <0.001    |
|                               | T1a ($n=29$)      | 1.3                     | 1.6 (0.32)               | 1.2 (−0.09)              | 1.1 (−0.17)            | 1.1 (−0.19)             | 1.0 (−0.29) | 0.027     |
|                               | T1b ($n=19$)      | 1.8                     | 2.4 (0.69)               | 2.1 (0.34)               | 1.7 (−0.08)            | 1.7 (−0.03)             | 1.9 (−0.15) | 0.003     |
|                               | T2 ($n=13$)       | 1.7                     | 1.9 (0.23)               | 1.8 (0.08)               | 1.6 (−0.07)            | 1.3 (−0.39)             | 1.7 (−0.01) | 0.198     |
|                               | Male ($n=51$)     | 1.5                     | 2.0 (0.48)               | 1.6 (0.11)               | 1.4 (−0.10)            | 1.4 (−0.12)             | 1.5 (−0.03) | <0.001    |
|                               | Female ($n=10$)   | 1.6                     | 1.6 (0.01)               | 1.5 (−0.12)              | 1.4 (−0.22)            | 1.0 (−0.58)             | 1.4 (−0.25) | 0.481     |

$\Delta$ difference between preoperative and the indicated follow-up time

### Table 3 Quality of life scores on the EORTC QLQ-C30

| EORTC QLQ-C30 item                  | Preoperative Mean | 6 weeks Mean | 3 months Mean | 6 months Mean | 1-year Mean | 2-years Mean | $p$ value |
|-------------------------------------|-------------------|--------------|---------------|---------------|-------------|--------------|-----------|
| Global health                       |                   |              |               |               |             |              |           |
| Global health status                | 77                | 81           | 83            | 81            | 81          | 81           | 0.047     |
| Functional scales                   |                   |              |               |               |             |              |           |
| Physical functioning                | 95                | 95           | 94            | 94            | 93          | 94           | 0.190     |
| Role functioning                    | 95                | 96           | 94            | 94            | 95          | 97           | 0.635     |
| Emotional functioning               | 72                | 85           | 85            | 87            | 88          | 90           | <0.001    |
| Cognitive functioning               | 89                | 91           | 89            | 92            | 91          | 88           | 0.362     |
| Social functioning                  | 92                | 93           | 95            | 96            | 95          | 95           | 0.402     |
| Symptom scales                      |                   |              |               |               |             |              |           |
| Fatigue                             | 20                | 15           | 14            | 15            | 17          | 12           | 0.118     |
| Nausea and vomiting                 | 1                 | 1            | 2             | 3             | 3           | 3            | 0.329     |
| Pain                                | 6                 | 7            | 3             | 4             | 7           | 5            | 0.173     |
| Dyspnea                             | 17                | 15           | 18            | 20            | 19          | 15           | 0.509     |
| Insomnia                            | 20                | 15           | 12            | 13            | 11          | 9            | 0.025     |
| Appetite loss                       | 5                 | 2            | 4             | 5             | 3           | 4            | 0.857     |
| Constipation                        | 5                 | 3            | 3             | 3             | 2           | 3            | 0.678     |
| Diarrhea                            | 4                 | 6            | 4             | 2             | 5           | 3            | 0.429     |
| Financial difficulties              | 6                 | 4            | 3             | 3             | 2           | 3            | 0.262     |
EORTC QLQ-HN35

The symptom scales showed low symptom scores at 2 years after treatment. As seen in the VHI questionnaire, gender had a significant effect on two items. Females had significantly lower mean scores than males on speech problems (10.6 points difference; \( p = 0.037 \)) and sticky saliva (11.8 points difference; \( p = 0.039 \)). At 2 years postoperatively, most complaints were about speech problems (male patients), sexuality, sticky saliva (male patients), coughing, and the use of painkillers; the scores for these items ranged between 11 and 17 points. Nevertheless, compared to preoperative values, both speech problems (\( \Delta 24, \ p < 0.001 \)) and coughing (\( \Delta 15, \ p = 0.002 \)) showed significant and clinically relevant improvements at 2 years. Pain also showed a significant improvement (\( \Delta 4; \ p = 0.02 \)), but this improvement did not qualify as clinically relevant. The improvement in speech problems among female patients was clinically relevant, but the change was not significant (\( \Delta 13, \ p = 0.691 \)) (Table 4).

Perceptual evaluation

The grade fluctuated significantly over time, and at 2 years, the pre- and postoperative values were similar (\( p < 0.001 \)). Initial deterioration was observed at 6 weeks. Thereafter, recovery was noted, and the grade stabilized between the 3- and 6-month time points. The tumor stage (T1a, T1b, and T2) had a significant impact on the grade (\( p = 0.001 \)). Patients with T1a tumors had significantly better end scores than patients with T1b tumors (difference in means: 0.76, \( p < 0.001 \)) and patients with T2 tumors (difference in means: 0.49, \( p = 0.031 \)). We found no significant difference between patients with T1b and T2 tumors (difference in means: 0.27, \( p = 0.256 \)). At 2 years, the grade declined compared to preoperative values only in patients with T1a tumors (\( \Delta 0.29 \); Table 2). Male and female patients did not have a mean difference in score (difference in means: 0.120, \( p = 0.644 \)), although male patients fluctuated significantly over time (\( p < 0.001 \)), whereas female patients did not (\( p = 0.481 \)).

Discussion

This prospective study investigated QoL and voice outcome for 2 years after TLM (unilateral type III resection or bilateral type II resection) in patients with early glottic carcinoma (extended T1 and limited T2). Our results indicate good overall QoL with low symptom scores. The VHI showed most improvement within the first 6 months. Interestingly, the VHI was significantly affected by gender; at 2 years after treatment, females showed scores

\[
\begin{array}{|l|c|c|c|c|c|c|c|}
\hline
\text{EORTC QLQ-HN35 item} & \text{Preoperative Mean} & \text{6 weeks Mean} & \text{3 months Mean} & \text{6 months Mean} & \text{1 year Mean} & \text{2 years Mean} & \text{p value} \\
\hline
\text{Symptom scales} & & & & & & & \\
\text{Pain} & 8 & 5 & 5 & 6 & 6 & 4 & 0.029 \\
\text{Swallowing} & 3 & 3 & 2 & 2 & 4 & 3 & 0.863 \\
\text{Senses problems} & 5 & 5 & 3 & 4 & 5 & 4 & 0.855 \\
\text{Speech problems (M)} & 38 & 31 & 20 & 18 & 13 & 14 & <0.001 \\
\text{Speech problems (F)} & 20 & 15 & 10 & 10 & 10 & 7 & 0.691 \\
\text{Trouble with social eating} & 2 & 2 & 2 & 2 & 2 & 2 & 0.970 \\
\text{Trouble with social contact} & 4 & 4 & 2 & 3 & 4 & 4 & 0.269 \\
\text{Less sexuality} & 14 & 15 & 17 & 15 & 18 & 17 & 0.905 \\
\text{Teeth} & 9 & 3 & 9 & 8 & 6 & 8 & 0.329 \\
\text{Opening mouth} & 3 & 2 & 2 & 2 & 5 & 2 & 0.220 \\
\text{Dry mouth} & 18 & 13 & 17 & 19 & 15 & 9 & 0.079 \\
\text{Sticky saliva (M)} & 15 & 16 & 12 & 10 & 15 & 13 & 0.363 \\
\text{Sticky saliva (F)} & 0 & 4 & 0 & 5 & 4 & 0 & 0.963 \\
\text{Coughing} & 28 & 21 & 21 & 22 & 16 & 13 & 0.002 \\
\text{Felt ill} & 10 & 7 & 5 & 5 & 8 & 8 & 0.459 \\
\text{Painkillers} & 13 & 8 & 10 & 7 & 12 & 11 & 0.333 \\
\text{Nutritional supplements} & 1 & 2 & 1 & 0 & 4 & 0 & 0.169 \\
\text{Feeding tube} & 0 & 0 & 0 & 1 & 0 & 0 & 0.451 \\
\text{Weight loss} & 9 & 7 & 1 & 5 & 4 & 9 & 0.037 \\
\text{Weight gain} & 5 & 19 & 19 & 23 & 17 & 7 & <0.001 \\
\hline
\end{array}
\]

\( M \) male, \( F \) female
within the normal range (8.7 points) and males showed slightly elevated scores (23.9 points). The grade score for dysphonia declined initially after surgery and showed most of the improvement or recovery within the first 6 months. The grade was significantly affected, not by gender but by tumor stage. At 2 years, the grade scores were between 1.0 (T1a) and 1.9 (T1b), which indicates mild (T1a) to moderate (T1b–T2) dysphonia. The final scores showed improvement for T1a tumors, but no change for T1b and T2 tumors, compared to preoperative grade scores.

This study is one of the first to find a significant effect of gender on the VHI questionnaire, although we could not confirm this in the perceptual evaluation. Both men and women showed improvements over time, but only female patients achieved clinically relevant improvements. However, most likely due to the small sample size of female patients, this improvement did not reach statistical significance. The female scores fluctuated over time, with an outlier score at 1 year. Therefore, in future studies with small groups, we recommend studying scores over time, rather than only evaluating two different time points. On the other hand, the improvement in male patients was statistically significant, but not clinically relevant. In contrast to these results, the study by van Gogh et al. reported no association between the VHI scores and gender, either in patients with voice impairments or in the population with normal glottic function [23]. However, in another study on patients with a variety of laryngeal diseases, Karlsen et al. found a correlation \( r = -0.17, p < 0.05 \) between the VHI score and gender; female patients had lower scores than male patients [30]. This latter finding was consistent with our results, although no exact VHI scores were given in that study [30]. The difference in VHI improvement between males and females might be explained by the fact that women show postoperative fundamental frequencies within the normal female range, whereas male patients show postoperative fundamental frequencies that are higher than the normal male range (van Loon et al. [18]). Potentially, this characteristic could lead male patients to experience a larger change in their voice and therefore to be less satisfied. The potential impact of gender on voice outcome after TLM for glottic carcinoma must be confirmed in future studies in larger patient populations. Until then, these results should be interpreted with caution.

The finding that patients with T1a tumors had significantly better grade scores than patients with T1b and T2 tumors might be explained by the fact that a lower tumor stage requires a smaller volume resection of the vocal cords [31, 32]. During the first 6 weeks, a temporary deterioration in grade was observed for tumors in all stages, followed by an initial recovery at 3 months. Between the 3rd and 6th months, the grade further improved and stabilized. This pattern was consistent with results reported in previous studies [33, 34]. At 2 years, only patients with T1a tumors showed significant improvements, compared to preoperative values.

After 6 months, only small changes in both the VHI and grade scores were observed. Therefore, improvements achieved at 6 months were indicative of the states achieved at 1 and 2 years postoperatively. Furthermore, the grade evaluations, showing mild to moderate dysphonia in both males and females, indicated that the voice did not return to normal levels after 2 years. This finding could be explained by the destructive effect of surgery on the vibratory layers of the vocal cord and the development of fibrosis. Interestingly however, the VHI did return to normal values for females and was only slightly elevated for males. This discrepancy between the VHI score and grade evaluation implies that there is a difference between what the patients experience and how experts rate their voices. This lack of correlation between the VHI questionnaire and the perceptual evaluation has been shown in other studies [12, 14, 35, 36]. A study by van Loon et al. investigated the time trade off in patients with laryngeal cancer and concluded that none of the patients who were treated with TLM was prepared to trade off years to live in perfect health. This shows that the perceived side effects (e.g., dysphonia) by patients are not substantial and that patients are able to cope well with their limitations in daily life [37]. QoL is a multidimensional construct; thus, it is best measured with an instrument that reports on multiple domains of functionality and well-being. Among the most widely used questionnaires in head and neck cancer research are those developed by the EORTC (QLQ-C30 and QLQ-HN35). These questionnaires have been used in many studies on patients with laryngeal cancer. However, they have been used in only a few studies on patients with early glottic cancer [10, 12, 16, 38, 39]. Three of these studies compared QoL in patients with early glottic cancer that were treated with either radiotherapy or TLM [10, 38, 39]. Two previous studies focused exclusively on patients that underwent TLM [12, 16]. The study of Hsin et al. prospectively investigated 62 patients with early glottic cancer (Tis-T2) that underwent TLM (ELS types I–VI) [16]. They demonstrated an immediate decline in QoL scores in the first few months, which recovered to baseline after 6 months, and then improved at 12 months, compared with preoperative scores. That finding is in contrast with findings in our study, because our patients did not report an immediate deterioration in QoL scores postoperatively. This difference might be explained by the fact that the previous study treated 15 patients (24%) with type IV–VI resections [16]; in contrast, we only treated patients with unilateral type III and bilateral type II resections.

Items on the QLQ-30 and QLQ-HN35 questionnaires have previously shown little differences in scores between men and women [40]. However, laryngeal cancer is less common in women than in men; thus, demonstrating
differences between the sexes can be challenging, due to the limited number of female patients. Several studies on either general populations or patients with laryngeal cancer have shown that women reported significantly worse QoL scores than men [41–44]. In our study, the data did not confirm this gender difference. On the contrary, we found that men reported significantly more problems of speech and sticky saliva than women did on the QLQ-HN35 items.

On both questionnaires (QLQ-C30 and QLQ-HN35), we observed slightly elevated values (12–17 points) for fatigue, dyspnea, speech (male patients), sticky saliva (male patients), coughing, and sexuality after 2 years of follow-up. Compared to normative data from the general Dutch population, QLQ-C30 items (fatigue and dyspnea) that were less than 10 points different from the reference group [44] were not considered clinically relevant. In the literature, no study has reported normative data for the QLQ-HN35 questionnaire; therefore, the other slightly elevated items (speech problems, sticky saliva, coughing, and sexuality) could not be compared to a reference. One multinational study analyzed data on 293 patients with laryngeal cancer (stages I–IV). Although that study tested the reliability and validity of the head and neck cancer module, it did not report normative data. They included patients that were newly diagnosed, had recurrent disease or were disease free (1–3 years after treatment), and were primarily treated with radiotherapy [24]. Compared to those results, our patients reported fewer problems. This discrepancy might be explained by the fact that they included larger tumors than those we included, and their patients were treated primarily with radiotherapy. In the future, it would be interesting to generate normative data for the QLQ-HN35 module to enable comparisons with healthy individuals.

The strengths of this study is the prospective design and the duration of the follow-up. Due to the long-term follow-up, we were able to show that the results at 6 months and 1 year, which are more common time frames for these types of study, are representative for the long term. Our results have therefore been useful to us in counselling patients who undergo these specific resections on what to expect—both in terms of end results and the time frame within which these are achieved. The study had some limitations. First, due to the longitudinal nature of our study and the inclusion of patients from three different hospitals, we could not avoid missing data, despite the prospective study design. In addition, we did not collect data on patient comorbidities and smoking after treatment. This could be of relevance and interesting for further research. Second, we did not collect data on speech therapy. However, all patients were instructed by the speech–language pathologist in vocal hygiene after TLM. No patient received speech therapy before 3 months after surgery. After that, speech therapy was administered on a case-by-case basis. We acknowledge that speech therapy can improve the voice results, and therefore we advocate the collection of data on speech therapy in future studies as suggested by Heijnen et al. [45]. Third, the sample size of female patients was small. Therefore, the significant effects of gender on the VHI and QLQ-HN35 questionnaire must be confirmed in future studies with larger sample size. Fourth, in the QLQ-HN35 we found a slightly elevated score in the item sticky saliva. Normally, you may expect elevated scores for sticky saliva after the treatment with radiotherapy and not after the treatment with TLM. However, no explanation could be given by the authors as to why sticky saliva showed elevated scores. Therefore, it would be interesting to generate normative data for this questionnaire.

Conclusion

Based on our findings, we conclude that patients with extended T1 and limited T2 tumors treated with TLM (unilateral type III or bilateral type II) show good QoL with low symptom scores and slightly elevated voice outcome data, at 2 years after treatment. Most of the improvement is observed within 6 months, and this level of improvement provides a clear indication of the status at 1 and 2 years post-operatively. These findings are useful for guiding patients in clinical decision making.

Acknowledgements We would like to thank Mrs. V.A.H. van de Kamp for her assistance in collecting voice data and voice evaluation.

Funding This study was awarded a Grant from ZOLEON, Stichting Oncologie Haaglanden West, Leiden, The Netherlands.

Compliance with ethical standards

Conflict of interest The authors declare no conflict interest.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent Informed consent was obtained from all individual participants included in the study.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
References

1. Nederlandse Werkgroep Hoofd Halstumoren, NWHHHT (2010) Richtlijnen Larynxcarcinomen Kwaliteitsinstituut voor de gezondheidszorg CBO 2010. Version 3.0. http://www.medinfo.nl/Richtlijnen/Oncologie/Hoofdhalstumoren/Larynxcarcinoom.pdf. Accessed Oct 2018

2. Warner L, Lee K, Homer JJ (2017) Transoral laser microsurgery versus radiotherapy for T2 glottic squamous cell carcinoma: a systematic review of local control outcomes. Clin Otolaryngol 42:629–636. https://doi.org/10.1111/ota.12790

3. Mendenhall WM, Werning JW, Hinerman RW et al (2004) Management of T1–T2 glottic carcinomas. Cancer 100:1786–1792. https://doi.org/10.1002/cncr.20181

4. Hartl DM, Ferlito A, Brasnu DF et al (2011) Evidence-based review of treatment options for patients with glottic cancer. Head Neck 33:1638–1648. https://doi.org/10.1002/hed.21528

5. Guimarães AV, Dedivitis RA, Matos LL et al (2018) Comparison between transoral CO2 laser microsurgery or radiotherapy for T2 glottic carcinoma. Curr Opin Otolaryngol Head Neck Surg 26:84–93. https://doi.org/10.1097/MOO.0000000000000438

6. Abdurehim Y, Hua Z, Yasin Y et al (2012) Transoral laser surgery versus radiotherapy: systematic review and meta-analysis for treatment options of T1a glottic cancer. Head Neck 34:23–33. https://doi.org/10.1002/hed.21686

7. Hendriksma M, Heijnjen BJ, Sjögren EV (2018) Oncologic and functional outcomes of patients treated with transoral CO2 laser microsurgery or radiotherapy for T2 glottic carcinoma. Curr Opin Otolaryngol Head Neck Surg 26:84–93. https://doi.org/10.1097/MOO.0000000000000438

8. Schrijvers ML, van Riel EL, Langendijk JA et al (2009) Higher supraglottic laryngectomy: a proposal for a classification by the working committee on nomenclature, European Laryngological Society. Eur Arch Oto-Rhino-Laryngol 266:993–998. https://doi.org/10.1007/s00405-008-0901-8

9. van Loon Y, Hendriksma M, Heijnjen BJ, van de Kamp VAH, Hakkesteegt MM, Böhringer S, Langeveld TPM, de Jong MA, Klooster WMC, Baatenburg de Jong RJ, Sjögren EV (2019) Voice outcome after unilateral ELS type III or bilateral type II resections for T1–T2 glottic carcinoma: results after 1 year. Head Neck. https://doi.org/10.1002/hed.25582

10. Jacobson BH, Johnson A, Grywalski C et al (1997) The Voice Handicap Index (VHI) development and validation. Am J Speech Lang Pathol 6:66–70. https://doi.org/10.1044/1058-0360.0603.66

11. Aaronsen NK, Ahmedzai S, Bergman B et al (1993) The European Organization for research and treatment for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376

12. Bjordal K, Ahlner-Elmqvist M, Tollesson E et al (1994) Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients. EORTC Quality of Life Study Group. Acta Oncol 33:879–885

13. Verdonck-De Leeuw IM, Kuik DJ, De Bodt M et al (2008) Validation of the voice handicap index by assessing equivalence of European translations. Folia Phoniatr Logop 60:173–178. https://doi.org/10.1159/000127836

14. Van Gogh CDL, Mahieu HF, Kuik DJ et al (2007) Voice in early glottic cancer compared to benign voice pathology. Eur Arch Oto-Rhino-Laryngol 264:1033–1038

15. Bjordal K, De G. Fayers PM, et al (2000) A 12 country field study of the EORTC QLC-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLC-H and N35) in head and neck patients. Eur J Cancer 36:1796–1807. https://doi.org/10.1016/S0959-8049(00)00186-6

16. Osoba D, Rodrigues G, Myles J et al (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144. https://doi.org/10.1200/JCO.1998.16.1.139

17. Bjordal K, Hammerlid E, Ahlner-Elmqvist M et al (1999) Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 17:1008–1019. https://doi.org/10.1200/JCO.1999.17.3.1008

18. Webb AL, Carding PN, Deary IJ et al (2004) The reliability of three perceptual evaluation scales for dysphonia. Eur Arch Oto-Rhino-Laryngol 261:429–434. https://doi.org/10.1007/s00405-003-0707-7

19. Hirano M (1981) Clinical examination of voice. Springer. New York

20. Beunckens C, Molenberghs G, Kenward MG (2005) Direct likelihood analysis versus simple forms of imputation for missing data in randomized clinical trials. Clin Trials 2(5):379–386

21. Karlsen T, Sandvik L, Heimdal JH et al (2017) Health-related quality of life as studied by EORTC QLQ and Voice Handicap Index among various patients with laryngeal disease. J Voice 31:251.e17–251.e26. https://doi.org/10.1016/j.jvoice.2016.07.009

22. Lester SE, Rigby MH, MacLean M, Taylor SM (2011) “How does that sound?”: objective and subjective voice outcomes following CO2 laser resection for early glottic cancer. J Laryngol Otol 125:1251–1255. https://doi.org/10.1017/S0022215111002490

23. Van Loon Y, Sjögren EV, Langeveld TPM et al (2012) Functional outcomes after radiotherapy or laser surgery in early glottic carcinoma: a systematic review. Head Neck 34:1179–1189

Springer
33. Chu P-Y, Hsu Y-B, Lee T-L et al (2012) Longitudinal analysis of voice quality in patients with early glottic cancer after transoral laser microsurgery. Head Neck 34:1294–1298. https://doi.org/10.1002/hed.21914

34. Mendelsohn AH, Matar N, Bachy V et al (2015) Longitudinal voice outcomes following advanced CO2 laser cordectomy for glottic cancer. J Voice 29:772–775. https://doi.org/10.1016/j.jvoice.2014.12.005

35. Nunez Batalla F, Caminero Cueva MJ, Senaris Gonzalez B et al (2008) Voice quality after endoscopic laser surgery and radiotherapy for early glottic cancer: objective measurements emphasizing the Voice Handicap Index. Eur Arch Oto-Rhino-Laryngol 265:543–548. https://doi.org/10.1007/s00405-007-0512-9

36. Sjogren EV, van Rossum MA, Langeveld TPM et al (2009) Voice profile after type I or II laser chordectomies for T1a glottic carcinoma. Head Neck 31:1502–1510. https://doi.org/10.1002/hed.21128

37. van Loon Y, Stiggelbout AM, Hakkesteegt MM et al (2017) Utility approach to decision-making in extended T1 and limited T2 glottic carcinoma. Head Neck 39:779–785. https://doi.org/10.1002/hed.24689

38. Stoeckli SJ, Guidicelli M, Schneider A et al (2001) Quality of life after treatment for early laryngeal carcinoma. Eur Arch Otorhinolaryngol 258:96–99

39. Laoufi S, Mirghani H, Janot F, Hartl DM (2014) Voice quality after treatment of T1a glottic cancer. Laryngoscope 124:1398–1401. https://doi.org/10.1002/lary.24445

40. Singer S, Wollbrück D, Wulke C et al (2009) Validation of the eortc QLQ-C30 and eortc QLQ-H&N35 in patients with laryngeal cancer after surgery. Head Neck 31:64–76. https://doi.org/10.1002/hed.20938

41. Hjermstad MJ, Fayers PM, Bjordal K et al (1998) Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core. J Clin Oncol 10.1007/s40273-012-0007-4

42. Tan S, Duong Dinh TA, Westhofen M (2016) Evaluation of gender-specific aspects in quality-of-life in patients with larynx carcinoma. Acta Otolaryngol 136:1201–1205. https://doi.org/10.1080/00016489.2016.1211319

43. Schwarz R, Hinz a (2001) Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer 37:1345–1351. https://doi.org/10.1016/S0959-8049(00)00447-0

44. Van De Poll-Franse LV, Mols F, Gundy CM et al (2011) Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer 47:667–675. https://doi.org/10.1016/j.ejca.2010.11.004

45. Heijnen BJ, Speyer R, Kertscher B et al (2016) Dysphagia, speech, voice, and trismus following radiotherapy and/or chemotherapy in patients with head and neck carcinoma: review of the literature. Biomed Res. Int. 2016:24

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.